We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Destiny Pharma Plc | LSE:DEST | London | Ordinary Share | GB00BDHSP575 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -1.50 | -8.96% | 15.25 | 849,260 | 12:21:22 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 15.00 | 15.50 | 16.75 | 15.25 | 16.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | -6.5M | -0.0683 | -2.23 | 14.53M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:21:24 | O | 60,000 | 15.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/4/2024 | 20:57 | ALNC |  TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well |
| 25/4/2024 | 07:00 | UK RNS | Destiny Pharma PLC Full year results and review of strategic options |
| 08/4/2024 | 07:00 | UK RNS | Destiny Pharma PLC Notice of Full Year Results |
| 19/3/2024 | 14:47 | UK RNS | Destiny Pharma PLC Exercise of Options and Total Voting Rights |
| 31/1/2024 | 18:28 | ALNC | EARNINGS AND TRADING: STV raises holding in Two Cities Television |
| 31/1/2024 | 07:00 | UK RNS | Destiny Pharma PLC Clinical development update |
| 22/1/2024 | 07:00 | UKREG | Destiny Pharma PLC Appointment of Nominated Adviser and Sole Broker |
| 04/1/2024 | 14:07 | ALNC | Destiny Pharma seeks to capitalise on XF-73 market potential in 2024 |
| 04/1/2024 | 07:00 | UKREG | Destiny Pharma PLC Year End Business Update |
| 20/10/2023 | 12:01 | ALNC | IN THE KNOW: Destiny Pharma's XF-73 is "the real deal" amid new data |
Destiny Pharma (DEST) Share Charts1 Year Destiny Pharma Chart |
|
1 Month Destiny Pharma Chart |
Intraday Destiny Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/4/2024 | 13:01 | Destiny Pharma plc | 2,901 |
| 22/11/2022 | 12:29 | Destiny Pharma | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 11:54:07 | 15.01 | 4,052 | 608.00 | O |
| 11:21:25 | 15.00 | 60,000 | 9,000.00 | O |
| 11:21:12 | 15.11 | 20,000 | 3,022.50 | O |
| 11:20:54 | 15.11 | 50,000 | 7,555.00 | O |
| 11:17:52 | 15.51 | 22,363 | 3,467.38 | O |
| Top Posts |
|---|
Posted at 26/4/2024 09:20 by Destiny Pharma Daily Update Destiny Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker DEST. The last closing price for Destiny Pharma was 16.75p.Destiny Pharma currently has 95,271,863 shares in issue. The market capitalisation of Destiny Pharma is £15,243,498. Destiny Pharma has a price to earnings ratio (PE ratio) of -2.34. This morning DEST shares opened at 16.75p |
Posted at 26/4/2024 11:25 by edmonda "A year of progress, and addressing the future", new research note is here: Destiny Pharma (LON:DEST) full-year results for the year ending December 31 2023 included news of a strategic review of the options for its lead program XF-73 nasal. Cost-controls and reduced clinical trial spend at this point in the development of Destiny’s assets reduced the loss for the year. With the increased focus on the partnering of XF-73 nasal, we were left in no doubt after the analysts’ meeting that XF-73 nasal is both a valuable asset and that it will be partnered at some point in time. While an external out-licensing transaction for XF-73 nasal similar to that for NTCD-M3 remains probable, the strategic update suggests a range of other options to achieve the same result for this asset. Our fair value for Destiny Pharma plc has changed to £212.0m (or 234p / share) from £254.7m (or 279p / share). This reflects the longer times until Phase 3 studies start and, as a result, its products launch at Destiny’s partners. It also reflects the vast global unmet need that XF-73 nasal can address. |
Posted at 25/4/2024 19:10 by briankrakow Thanks for flagging up the interview with Vadim Alexandre. Valid point about the 'strategic review.' Did they need to mention it?The optimistic scenario on this is that the new plan for the Phase 3 trial will lead to a deal in the autumn, and no further funding will required. If that happens, the current share price will be an absolute steal. The pessimistic scenario is that there will have to be a very dilutive fundraising or the strategic review will lead to another very dilutive outcome that I haven't even thought of. Frankly, at £16 million, there's an argument for putting on XF-73 on hold and waiting for M3 to develop. Better that than horrendous dilution in my view. |
Posted at 25/4/2024 07:57 by bones698 What they think the company is worth and what the market thinks are probably very wide apart however anyone looking to acquire wil gonoff the current mkt cap and not what the current ceo thinks. Hence no deals or offers imo. If management were any good they would have raised with the share price higher months ago. Now it's a big problem they face and shareholders will pay the priceSub 15p today maybe 13p by eod |
Posted at 23/4/2024 15:56 by wh1spa If someone were to buy a 25% stake here on the open market , what affect would this have on the share price So if a fundraising is in the offing I'm hoping for a premium to today's price. |
Posted at 29/2/2024 13:37 by marvelman Amaretto...thanks for the heads up re post 2795. I thought I would take a look at his rants on other threads and cannot believe he has the front to preach to us here when he is a self confessed loser:-bones699 - 27 Feb 2024 - 22:40:53 - 1672 of 1859 My AGL investment sucks my average share price is 40p current share price 12p its a basket case just like me! |
Posted at 06/2/2024 09:19 by arab3 Love this bb, share price plummet everyone disappears share price rise back they come! |
Posted at 31/1/2024 15:22 by edmonda Clinical Development Updates - new research note with audio summary from Equity Development here: Destiny Pharma has started the year with two important clinical development updates on its lead products which enhance both their profiles. The clinical development update on XF-73 Dermal, which is a variation on Destiny’s XF-73 Nasal product included a preclinical study of an XF-73 Dermal formulation demonstrating that like XF-73 Nasal, it is also safe and applications to wounds results in negligible systemic levels. On the non-toxigenic Clostridioides difficile strain M3, Destiny and partner Sebela Pharmaceuticals improved M3’s chemistry, manufacturing and controls program to incorporate a solid dose, rather than liquid formulation – which should improve patient compliance, manufacturing and storage costs – and changed the product’s contract manufacturer. While these changes may necessitate a bridging study between the two dosage forms, the costs all future M3 studies will be met by Destiny’s partner. Our fair value remains unchanged at £245.7m, or 279 pence per share. |
Posted at 30/10/2023 09:50 by xxproinvestorxx This month Bill turned 61 so I would presume retirement is something on his mind. Dest is his only appointment as a director, so it is logical to assume his 6.5M shares constitutes a large proportion of his net wealth. The only way for him to extract any value, would be to sell his shares. However, doing so on the open market would be devastating to the share price.Of course, he could be waiting for further value inflection points and the completion of Phase 3 trials for M3 and/or XF-73, however it will be several years before Dest reach commercialisation should P3 trials be successful. Additional funding is also likely to be required (depending upon XF-73 deal terms) and, currently, it is probable that this would come from share placements, albeit at considerably higher market cap and share price than present. Of course this is all speculation on my part, but I'd like to know others thoughts? |
Posted at 30/10/2023 09:21 by xxproinvestorxx I'm surprised at the slip back in share price last week but then this is the Aim market.One thing I find curious is that both Chris and Bill have transferred a large proportion of their shares to their spouses in the past month. Bills are particularly intriguing, with 2.3M shares transferred on the 4th Oct. Chis has only just joined the company so there is less weight behind his transfer as he transferred the share shortly after purchasing them. But this still raised the question - why have they both transferred such a large number of shares? And why now? The shares were not transferred (by Bill) prior to the M3 deal, or had much interaction with the share in the past two years. The only logical conclusion I can deduce is that it optimises and reduces their taxes. However, this would only be a consideration if they are a. expecting a significant uplift in the share price and b. expecting to exit soon. We know they are searching for a partner for XF-73, but could a full acquisition be on the cards? And if so what price would someone have to pay? The current climate is pretty dire for raising capital, and there has been a drop-off in pharma deals recently, but many large pharma companies are sitting on large cash stock-piles. In addition, Dest have a significant advantage and are de-risked compared with other small pharma companies listed on Aim - with M3 & XF-73 both Phase 3 ready, a partner and deal worth up to $570M + royalties for the former, and, cash runway into 2025. |
Posted at 31/7/2023 20:07 by mrk74 Bones698,agreed Phase 3 trial data will be sometime in coming but there are many more milestones/share price drivers for Dest between now and then. As you know, the real catalyst to drive the share price over the next 3-9months is a partnership on XF-73 nasal (NB the report published today references XF-73 dermal - an earlier stage/ different workstream/programme and a whole different opportunity set). The collabaration you refer to with not much money upfront is for the development of NTCD-M3 where Sebela have agreed to fully fund the development to commercialisation of the product in return for US rights (RoW partnerships still in play). Sebela paid Dest $1m upfront, have agreed to pay another $19m in development milestone payments and sales revenue payments up to $550m (plus royalties on top). Agreed, the upfront payment could be argued to be disappointing but the cost to Sebela to fully fund the development needs to be included in the equation too. Irrespective, I dont think any investor/anyone with knowledge of Destiny would argue that the real value is more likely to be in the XF-73 platform and in particular in the XF-73 nasal partnership agreement as and when it comes. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
